TP53 Codon 72 Polymorphism Linked to Poor Prognosis in Advanced Gastric Cancer Patients

Strategic Insights -

Scientists at Kyungpook National University have discovered that a specific polymorphism in the TP53 codon 72 gene is associated with a lower response rate to chemotherapy and poor prognosis in patients with advanced gastric cancer. The study, published in Cancer Chemotherapy and Pharmacology, analyzed the genomic DNA of 57 patients treated with paclitaxel and cisplatin combination chemotherapy and found that the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to the treatment.

Key Takeaways:

  • The study analyzed the polymorphisms of apoptosis-related genes in 57 patients with advanced gastric cancer treated with paclitaxel and cisplatin combination chemotherapy.
  • The TP53 codon 72 polymorphism was significantly correlated with a lower response rate to the combination chemotherapy, with 35.7% of patients with the Arg/Pro and Pro/Pro genotypes responding to the treatment compared to 66.7% of patients with the Arg/Arg genotype.
  • A multivariate survival analysis showed that the time to progression for patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 was worse than for patients with the Arg/Arg genotype (Hazard ratio = 3.056, P-value = 0.047).
  • The researchers concluded that the TP53 codon 72 SNP is predictive of the response to chemotherapy and correlates with the time to progression in patients with advanced gastric cancer.
  • The study highlights the importance of genetic profiling in predicting treatment outcomes for patients with advanced gastric cancer.

Statistics:

  • 57 patients with advanced gastric cancer were enrolled in the study.
  • 35.7% of patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 responded to the combination chemotherapy.
  • 66.7% of patients with the Arg/Arg genotype responded to the combination chemotherapy.
  • The Hazard ratio for the time to progression for patients with the Arg/Pro and Pro/Pro genotypes was 3.056 (P-value = 0.047).
  • The study was published in Cancer Chemotherapy and Pharmacology (Volume 64, Issue 2, 2009).

Sources:

  • Kim, J.G., et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemotherapy and Pharmacology, 2009;64(2):355-360.
  • Cancer Chemotherapy and Pharmacology (Journal)